Statements (24)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:acquiredBy |
gptkb:Novartis
|
| gptkbp:country |
gptkb:United_States
|
| gptkbp:developedBy |
cancer therapies
|
| gptkbp:FDAApproved |
Rubraca (2016)
|
| gptkbp:filedForBankruptcy |
2022
|
| gptkbp:focusesOn |
oncology
|
| gptkbp:founded |
2009
|
| gptkbp:founder |
Patrick J. Mahaffy
|
| gptkbp:headquarters_location |
gptkb:Boulder,_Colorado,_United_States
|
| https://www.w3.org/2000/01/rdf-schema#label |
Clovis Oncology
|
| gptkbp:industry |
gptkb:biotechnology
|
| gptkbp:notableProduct |
gptkb:Fusilev
gptkb:Lucitanib Rubraca |
| gptkbp:numberOfEmployees |
~400 (2022)
|
| gptkbp:stockSymbol |
CLVS
|
| gptkbp:tradedOn |
NASDAQ: CLVS
|
| gptkbp:website |
https://www.clovisoncology.com/
|
| gptkbp:bfsParent |
gptkb:Abingworth
gptkb:CARIN_Alliance gptkb:Rucaparib gptkb:Lucitanib |
| gptkbp:bfsLayer |
8
|